Background: Previous GWAS studies have shown that there is a relationship between M3 muscarinic acetylcholine receptor  (CHRM3 ) rs2165870 polymorphism and postoperative nausea and vomiting (PONV) incidence. However, no Chinese studies have addressed this issue.
Methods: To explore the relationship between CHRM3  rs2165870 polymorphism and PONV incidence in a Chinese Han population, we enrolled 512 patients receiving elective surgery in this study. CHRM3  rs2165870 polymorphism was genotyped using PCR-RFLP method.
Results: We found that AA genotype or A allele of CHRM3  rs2165870 polymorphism elevated the risk of PONV (AA versus GG; OR, 2.88; 95% CI, 1.51– 5.47; P = 0.001; A versus G; OR, 1.39; 95% CI, 1.07– 1.81; P = 0.013). In addition, CHRM3  rs2165870 polymorphism was related to the risk of PONV among the males, smokers, and those individuals with Apfel Score 3– 4 or ASA classification 2– 3. Last, we assessed the effects of CHRM3 rs2165870 polymorphism on the treatment efficacy of ondansetron for PONV. Data uncovered that 103 of 209 patients (49.3%) showed response to ondansetron treatment for PONV. The PONV incidence was significantly higher in AA genotype carriers compared with GG genotype carriers during the first 2 h after surgery, but not from 2 to 24 h after surgery.
Conclusion: To sum up, this study reveals that CHRM3  rs2165870 polymorphism is related to the incidence of PONV and treatment effects of ondansetron for preventing PONV in this Chinese Han population.
Keywords: postoperative nausea and vomiting, CHRM3 , single nucleotide polymorphism, ondansetron